Compare HXL & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HXL | ADMA |
|---|---|---|
| Founded | 1946 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.1B |
| IPO Year | N/A | N/A |
| Metric | HXL | ADMA |
|---|---|---|
| Price | $73.39 | $19.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $72.88 | $28.50 |
| AVG Volume (30 Days) | 1.3M | ★ 2.9M |
| Earning Date | 01-21-2026 | 11-05-2025 |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | N/A | ★ 205.35 |
| EPS | 0.84 | ★ 0.86 |
| Revenue | ★ $1,876,400,000.00 | $488,559,000.00 |
| Revenue This Year | $0.16 | $22.19 |
| Revenue Next Year | $10.49 | $24.33 |
| P/E Ratio | $86.65 | ★ $23.11 |
| Revenue Growth | N/A | ★ 27.63 |
| 52 Week Low | $45.28 | $13.50 |
| 52 Week High | $79.20 | $25.67 |
| Indicator | HXL | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 50.64 | 65.11 |
| Support Level | $71.98 | $19.13 |
| Resistance Level | $79.20 | $20.46 |
| Average True Range (ATR) | 1.85 | 0.68 |
| MACD | -0.52 | -0.01 |
| Stochastic Oscillator | 19.53 | 65.34 |
Founded in 1948, Hexcel designs and manufactures a range of highly engineered composite fibers, fabrics, resins, and structures for use in the commercial aerospace, defense, and high-performance automotive markets. These are lighter than metal and perform under rigorous conditions in aircraft frames, wings, engines, and other components and subassemblies. The company's name derives from the six-sided honeycomb structures that lend many of its products their light weight and rigidity. Hexcel's biggest customers are Airbus (40% of 2024 sales) and Boeing (15% of 2024 sales; 25% before the pandemic) and their respective subcontractors.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.